Vir Biotechnology Net Income

Vir Biotechnology (VIR) currently reports a net income of $-250M as of June 2026. That compares with $-550M in the prior-year period — up 54.3% year over year. That is below the Healthcare sector average of $16B. Use the charts on this page to explore Vir Biotechnology's net income history and peer comparisons.

Vir Biotechnology's net income increased from $-550M to $-250M — a 54.3% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Vir Biotechnology's net income of $-250M is lower than the Healthcare sector average of $16B. That is roughly 101.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Vir Biotechnology reported $-250M in net income as of June 2026. That compares with $-550M in the prior-year period — up 54.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $-250M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $16B. From there, open related valuation or income-statement pages for Vir Biotechnology, and consider following VIR for alerts when major investors trade the stock.